Sol Gel Twyneo reduces acne marks in late-stage studies

Sol Gel Technologies Ltd's Twyneo is a once-daily topical non-antibiotic cream containing a fixed-dose combination of encapsulated benzoyl peroxide and tretinoin.

New Delhi: Sol Gel Technologies Ltd said on Monday its lead acne drug candidate, Twyneo, met the main goal of reducing marks in two late-stage studies.

Twyneo is a once-daily topical non-antibiotic cream containing a fixed-dose combination of encapsulated benzoyl peroxide and tretinoin.

Read Also: Glenmark gets USFDA nod for a generic version of Epiduo gel to treat acute acne

Acne is a common skin disease that affects about 40 million to 50 million people in the United States, according to the American Academy of Dermatology.

Read Also: Foamix Pharma wins USFDA nod for Amzeeq, topical minocycline treatment for acne